Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Maridebart Cafraglutide

Extension Trial to Evaluate the Long-term Efficacy, Safety, and Tolerability of Maridebart Cafraglutide (MARITIME-1-EXTENSION)

Amgen · Phase 3 · Recruiting · Enrollment 3200

NCT07684235

ArmPopulationDoseWeeksEstimandWeight change
Maridebart Cafraglutide Low Dose Q4WObesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide Medium Dose Q4WObesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide Medium Dose Q8WObesity or overweightn/rn/rn/rn/r
Placebo Q4W (Received Medium Dose Maridebart Cafraglutide in Parent Trial)Obesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide High Dose Q4WObesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide High Dose Q8WObesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide High Dose Q12WObesity or overweightn/rn/rn/rn/r
Placebo Q4W (Received High Dose Maridebart Cafraglutide in Parent Trial)Obesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide High Dose Q4W (Received Placebo in the Parent Trial)Obesity or overweightn/rn/rn/rn/r
Maridebart Cafraglutide Low Dose Q4W(Received Very Low Dose Maridebart Cafraglutide in Parent Trial)Obesity or overweightn/rn/rn/rn/r